



South Alabama Medical Science Foundation  
Cash Receipts (For Projects Over \$2,000)  
October 1, 2022 - September 30, 2023

Department	Project Number	Project Title	Principal Investigator	Source of Funding	22-23 Receipts
Neurology	63867	A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the safety, Tolerability and Efficacy of XEN1101 as Adjunctive Therapy in Focal-onset Epilepsy (Xenon XPF-008-201)	Dr Naritoku, D	Xenon Pharmaceuticals, Inc.	

South Alabama Medical Science Foundation  
Cash Receipts (For Projects Over \$2,000)  
October 1, 2022 - September 30, 2023

Department	Project Number	Project Title	Principal Investigator	Source of Funding	22-23 Receipts
OB-GYN	63887	A Phase 3, Randomized, Double- or Observer-Blinded, Placebo-Controlled Trial to EvaluateThe Efficacy and Safety of a Respiratory Syncytial Virus (RSV) Perfusion FSubunit Vaccine in Infants Born to Women Vaccinated During Pregnancy			



South Alabama Medical Science Foundation  
 Cash Receipts (For Projects Over \$2,000)  
 October 1, 2022 - September 30, 2023

Department	Project Number	Project Title	Principal Investigator	Source of Funding	22-23 Receipts
Surgery	63879	Use of Nexobrid for Treatment of Acute Deep Partial and Full Thickness Burn Injuries (MediWound MW2018-06-21)	Dr Bright, A	Mediwound	6,128.52
(e)7-33810	33810	The CALIBER Study: Randomized Controlled Trial of LINX versus Double-Dose Pump Inhibitor Therapy in the Treatment of Gastroesophageal Reflux Disease (TRX_2018_01)	(b)7-33810 (o)7-33810	Ethicon Endo-Surgery, Inc	252.00

South Alabama Medical Science Foundation  
 Cash Receipts (For Projects Over \$2,000)  
 October 1, 2022 - September 30, 2023

Department	Project Number	Project Title	Principal Investigator	Source of Funding	22-23 Receipts
	62648	Royalty On Sales of Antibody Products	Dr Scammell, J	QED Bioscience	3,457.60
				Total Other Research	<u>3,457.60</u>
				Total	<u><u>325,252.25</u></u>